Antibe Therapeutics’ Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease

Antibe Therapeutics Inc.’s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn’s Disease and Ulcerative Colitis, collectively known as “inflammatory bowel disease” (IBD).

IBD affects almost 200,000 Canadians, and many millions of others worldwide. The incidence of IBD is increasing, particularly in young children. There is no cure for IBD, and treatment options are limited and often inadequate.

Dr. Wallace’s research group demonstrated a key role of hydrogen sulfide in promoting repair of intestinal injury. Using mice having a genetic defect similar to that found in many IBD patients, the research demonstrated that small amounts of hydrogen sulfide-releasing agents could rapidly reduce the intestinal inflammation and ulceration that developed in these mice.

Dr. Wallace commented: “We are excited by the results of this study and very grateful to Crohn’s Colitis Canada and the Canadian Institutes of Health Research for funding this research”.

The article can be accessed via the following link:
http://www.antibethera.com/Articles/PNAS_2014

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.